Formosa Pharmaceuticals is a clinical stage biopharmaceutical company with primary focus in the areas of ophthalmology and oncology.

In August, 2017, Formosa Pharmaceuticals acquired Activus Pharmaceuticals (Funabashi, Japan), which afforded Formosa Pharmaceuticals a proprietary Active Pharmaceutical (ingredient) Nanoparticle Technology (APNT^®), and two late-stage preclinical assets in ophthalmology. Of these ophthalmology candidates, the NDA for APP13007 has been approved by US FDA for inflammation and pain after ocular surgery.

Collaborating with global strategic partners, Formosa Pharmaceuticals has assembled a unique pipeline of diverse assets. Each opportunity has a different risk profile and enjoys a unique advantage with respect to the company’s resources, infrastructure, and network.

Formosa Pharmaceuticals continues to seek additional valued partnerships to complement its existing pipeline and platform technologies.